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Oligoastrocytoma: Who's afraid of the ... Liger? 
 
Sir, 
We thank Dr Bai and colleagues1 for their comments concerning our paper regarding the 
diagnostic utility of ATRX/IDH1 immunohistochemisty in oligoastrocytomas2.  
 
We agree with the authors' attitude toward fostering the principle of parsimony (also known 
as Ockham's razor3) – whereby no unnecessary entities/labels should be posited whenever 
a phenomenon can be reduced to a set of less complex constituents. Nevertheless, we take 
issue with some of the shortcuts which we feel they engaged in along their line of reasoning. 
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Foremost, it was neither our intention nor the actual message of our paper to – as Dr Bai 
and colleagues put it – "provide evidence for a biologic or genetic signature specific to 
[oligoastrocytoma]". Quite on the contrary, our study design was based on the explicit 
premise "that [oligoastrocytomas] actually should be considered as «morphologically 
ambiguous» rather than «mixed»". 
 
A (hypothetical) analogy may help to clarify our point (Table 1). For the sake of argument, 
we assume that some individuals within the genus Panthera could not be classified 
unequivocally as either lion or tiger based on their morphological traits alone. Zoologists 
might have grown to apply the descriptive term liger to such ambiguous specimens. 
Furthermore, we assume there was a classical test that would react positive in almost all 
animals that looked like a typical tiger as well as in some ligers; conversely, it would react 
negative in almost all morphologically typical lions (and any other unrelated species). 
Subsequent research would have shown that almost all ligers are either lions or tigers 
biologically and that their true nature was closely correlated with the respective results of the 
above classical test. 
 
This deliberately overdrawn paraphrase of our working paradigm may illustrate why, in our 
opinion, some of the statements by Dr Bai and colleagues' inadequately reflect the paper's 
content. 
 
First, a purported caveat that liger – as counterpart of oligoastrocytoma – "frequently 
presents with heterogeneous morphology" is simply a tautology, because it was defined in 
the first place as not being clear cut. In terms of our thought experiment, if someone had 
demonstrated that animals classified as ligers had a higher chance of genetically being 
tigers if they look more like tigers, the objection that the "morphological score" adopted in 
that particular study "can be significantly biased by the interpretation preferences of three 
[zoologists] at a single institution and their tendency to agree with each other" would become 
moot. More generally, advice that "morphological scores should be based on the presence 
of certain […] features rather than the preferences of [zoologists] at a single institution" 
would miss the key point of the study, which rather than attempting to define a normative 
standard of practice, would have been to provide a proof of principle.  
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Second, we feel that one major argument in Dr Bai and colleagues' criticism of our approach 
is flawed semantically. "Subjectivity" – as used in the context by these authors – should not 
be equated to "arbitrariness". Some degree of subjectivity in pathological diagnosis is 
probably inevitable to compensate for the actual fuzziness of supposedly "objective" criteria. 
Lack of awareness of such dialectics is prone to end in diagnostically unproductive short 
circuits in the form of misplaced concreteness4 – in the specific case of our subject matter: in 
mistaking diagnostic criteria of an entity for the entity itself. By such reasoning, an 
oligodendroglioma with neurocytic differentiation5 (or a tiger without a tail) would not be 
recognized as oligodendroglioma (or tiger), because they deviated from previously 
established diagnostic criteria by a detail that has not been pre-specified. 
 
The point we did try to make is: even in what is a morphological grey zone by definition, 
morphology is able to predict to some extent the underlying biological nature. In our 
perception, this emphasizes the value of careful morphological assessment (while we do 
acknowledge its limitations). 
 
To make our analogy come full circle: in our thought experiment the question would not be if 
liger "should be a distinct entity", but rather if the term liger should be further applied to 
morphologically ambiguous animals. It might be considered perfectly acceptable to do so, as 
long as it were done on the understanding that almost all of these were biologically either 
lions or tigers, with true ligers (i.e., hybrids) being exceedingly rare. 
 
Along the same line, one may well consider the term "oligoastrocytoma" acceptable, if it is 
implied to indicate a morphological grey zone in histopathological terms rather than a 
biologically distinct entity. Alternatively, one may prefer a non-committal terminology such as 
e.g. "diffuse glioma, IDH1-mutant, NOS, with morphological features intermediate between 
astrocytoma and oligodendroglioma, LOH testing pending”.  
 
This question, however, is one of terminology alone and independent of the scientific 
observation that true hybrid tumours are exceedingly rare.6  Furthermore, we do not believe 
that any real-life diagnostic difficulties will be resolved just by eliminating the term 
"oligoastrocytoma".  
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Subject matter IDH-mutant gliomas Genus Panthera 
Species #1 Oligodendroglioma Tiger 
Species #2 Astrocytoma Lion 
Traditional terminology 
for morphologically 
ambiguous cases 
Oligoastrocytoma (Hypothetical) Liger 
Classical test LOH 1p19q Hypothetical classical test 
positive in tigers  
Newer markers IDH1/2, ATRX Hypothetical newer markers 
Possible non-committal 
terminology 
Diffuse glioma, IDH1-mutant, 
NOS, with morphological 
features intermediate between 
astrocytoma and 
oligodendroglioma 
Panthera, NOS, with 
morphological features 
intermediate between lion and 
tiger 
Rare true hybrid True oligoastrocytoma True liger 
Professionals Pathologists Zoologists 
Table 1: Overview of the analogies used in the text to illustrate the conceptual difference 
between grey zone and hybrid.   
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